PDCD1 and cancer: The modulation of the PD-1/PD-L1 pathway (by inhibiting the interaction between PD-1 and PD-L1) has been shown to increase T-cell activity with beneficial effects in cancer control and cure using monoclonal antibodies (e.g., IgG4) [77,78,79,80].